Pharmaceutical Executive
Following its economic rise in recent decades, driven by innovation across a wide variety of powerhouse industries, South Korea is setting its sights on the next generation of technological growth-including new strategies to globalize and industrialize the nation’s pharmaceutical and healthcare sector.
Sometimes dubbed the “Miracle on the Han,” South Korea is indisputably an economic success story. Finding itself one of the world’s poorest countries in 1953 following the devastation of the Korean War, its meteoric development in the decades since has seen GDP per capita surge 31,000-fold, elevating the country to the world’s 11th largest economy.
With a population dwarfed by those of Asian rivals such as China and Japan, Korea’s success has come from innovation and the country now regularly tops the Bloomberg Innovation Index. Today Korea leads in industrial competitiveness for smartphones, semiconductors, and lithium batteries, and has created world-renowned conglomerates, known as Chaebols, such as Samsung, Hyundai, and LG. The products of Korean innovation stretch across a wide variety of industries; even the world’s first ice-breaking carrier for transporting liquefied natural gas (LNG) calls Korea its manufacturing home.
As other nations seek to emulate Korea’s standing within its historical powerhouse industries, the country’s government has already set its sights on the next generation of technologies ripe for Korean dominance. Under the presidency of Moon Jae In, Korea is gearing up to embrace the fourth industrial revolution, fusing the physical, digital, and biological worlds.
“When innovative growth is discussed, the strategy includes all sectors of the economy, including pharmaceuticals and the health sector,” asserts Yong Ik Kim, president of the National Health Insurance Service (NHIS). Such sentiments tend to be echoed by the legislators and policymakers, many of whom seem to understand the life science industry’s fundamental importance as a lynchpin to economic resurgence.
“We really need to think carefully about how to globalize and industrialize the healthcare sector. For example, which new technologies, and therapies to pursue,” insists Myoung Su Lee, chairman of the Health and Welfare Committee at the National Assembly of the Republic of Korea.
To view the full article on Korea's evolving life sciences and healthcare markets, produced by Focus Reports and featured in Pharm Exec's May 2019 issue, click
here(cycle down to page 30).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.